BioSig Technologies to Acquire PediaTrust, LLC
Ticker: STEX · Form: 8-K · Filed: May 28, 2024 · CIK: 1530766
| Field | Detail |
|---|---|
| Company | Biosig Technologies, Inc. (STEX) |
| Form Type | 8-K |
| Filed Date | May 28, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $2.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, healthcare, pediatrics
TL;DR
BioSig buying PediaTrust to boost pediatric offerings. Deal expected Q3.
AI Summary
BioSig Technologies, Inc. announced on May 28, 2024, that it has entered into a definitive agreement to acquire PediaTrust, LLC. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions. This move aims to expand BioSig's product offerings and market reach within the pediatric healthcare sector.
Why It Matters
This acquisition could significantly expand BioSig's presence in the pediatric market and diversify its revenue streams.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and the possibility of not achieving projected synergies.
Key Players & Entities
- BioSig Technologies, Inc. (company) — Registrant
- PediaTrust, LLC (company) — Acquisition Target
- May 28, 2024 (date) — Announcement Date
- Third Quarter of 2024 (date) — Expected Closing Period
FAQ
What is the primary strategic goal of BioSig Technologies, Inc. in acquiring PediaTrust, LLC?
The primary strategic goal is to expand BioSig's product offerings and market reach within the pediatric healthcare sector.
When is the acquisition of PediaTrust, LLC expected to be completed?
The acquisition is expected to close in the third quarter of 2024.
Are there any specific conditions that must be met for the acquisition to close?
Yes, the acquisition is subject to customary closing conditions.
What industry segment does PediaTrust, LLC operate in?
PediaTrust, LLC operates within the pediatric healthcare sector.
What is the filing date of this Form 8-K?
The filing date of this Form 8-K is May 28, 2024.
Filing Stats: 445 words · 2 min read · ~1 pages · Grade level 12.8 · Accepted 2024-05-28 17:20:57
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M
- $2.5 million — he Nasdaq Capital Market, including the $2.5 million stockholders' equity requirement set fo
Filing Documents
- form8-k.htm (8-K) — 35KB
- 0001493152-24-021649.txt ( ) — 204KB
- bsgm-20240528.xsd (EX-101.SCH) — 3KB
- bsgm-20240528_lab.xml (EX-101.LAB) — 33KB
- bsgm-20240528_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: May 28, 2024 By: /s/ Anthony Amato Name: Anthony Amato Title: Chief Executive Officer